|
Media Releases |
Financial Reports |
Presen-tations |
|
03/28/2007
|
|
|
|
| Annual General Meeting Lonza Group Ltd of 28 March 2007 |
Today’s Annual General Meeting of Lonza Group Ltd led by the Chairman of the Board of Directors, Rolf Soiron, was attended by 325 shareholders. They represented 29,34% of the sharecapital.
The Shareholders carried all motions proposed by the Board of Directors.
A dividend of CHF 1.50 per share will be paid out on 3 April 2007.
Dame Julia Higgins, Peter Kalantzis, Gerhard Mayr, Rolf Soiron, Sir Richard Sykes and Peter Wilden were all elected for a further term in office of one year.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value added chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006 Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor Relations /Media inquiries:
Lonza Ltd
Margot Connor
Tel +41 61 316 8566
Fax +41 61 316 9566
Mobile +41 79 401 2832
margot.connor@lonza.com
Media inquiries German:
Lonza Ltd
Dominik Werner
Tel +46 61 316 8798
Fax +41 61 316 9798
Mobile +41 79 470 6308
dominik.werner@lonza.com
|
|
|
